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Abstract. 
 
The glucocorticoid receptor (GR) mediates 
the biological effects of glucocorticoids (GCs) through 
activation or repression of gene expression, either by 
DNA binding or via interaction with other transcription 
factors, such as AP-1. Work in tissue culture cells on the 
regulation of AP-1–dependent genes, such as collage-
nase (MMP-13) and stromelysin (MMP-3) has sug-
gested that the antitumor and antiinﬂammatory activity 
of GCs is mediated, at least in part, by GR-mediated 
downmodulation of AP-1. Here, we have identiﬁed 
phorbol ester-induced expression of MMP-3 and
MMP-13 in mouse skin as the ﬁrst example of an in vivo 
system to measure negative interference between AP-1 
and GR in the animal. Cell type-speciﬁc induction of 
these genes by tumor promoters is abolished by GCs. 
 
Importantly, this is also the case in GR
 
dim
 
 mice express-
ing a DNA binding-defective mutant version of GR.
In contrast, the newly identiﬁed target genes in skin, 
plasma glutathione peroxidase and HSP-27, were in-
duced by GC in wild-type, but not in GR
 
dim
 
 mice. Thus, 
these data suggest that the DNA binding-independent 
 
function of the GR is dispensable for repression of AP-1 
activity in vivo and responsible for the antitumor pro-
moting activity of GCs.
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LUCOCORTICOIDS
 
 (GCs)
 
1
 
 are in widespread medical
use to inhibit inflammatory processes. Further-
more, they are known to block experimentally in-
duced tumorigenesis, such as phorbol ester-induced multi-
step carcinogenesis in mouse skin (Belman and Troll,
1972). These biological activities of GCs are mediated by
positive or negative regulation of gene expression via
binding to the glucocorticoid receptor (GR), a member of
the steroid hormone receptor superfamily, which acts as a
ligand-induced transcription factor (Beato et al., 1995).
Different modes of action of transcriptional regulation by
GR have been described. Upon ligand-induced dimeriza-
tion the GR binds to conserved DNA motifs known as glu-
cocorticoid response elements (GRE) and negative acting
GREs (nGREs), respectively, to positively or negatively
regulate gene expression (Beato et al., 1995; Karin, 1998).
Second, mutual interference between GR and other tran-
scription factors, such as AP-1 and NF
 
k
 
B, does not require
DNA binding of the GR, but rather is mediated by inter-
action with these factors (Beato et al., 1995; Karin, 1998).
The physiological importance of the dimerization- and
DNA binding-independent repression function of GR was
documented in homozygous mice carrying a DNA bind-
ing-defective mutant of GR (GR
 
dim
 
). In these mice, DNA
binding and, as a consequence, transcriptional regulation
of target genes containing GREs and nGREs was im-
paired, whereas repression of AP-1–mediated gene ex-
pression in primary embryonic fibroblasts was normal
(Reichardt et al., 1998). In contrast to GR-deficient mice,
 
GR
 
dim
 
 mice survive until adulthood (Cole et al., 1995;
Reichardt et al., 1998), suggesting that the capacity of the
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Abbreviations used in this paper:
 
 GCs, glucocorticoids; GR, glucocorti-
coid receptor; GR
 
dim
 
, mice homozygous for a mutation in the endogenous
GR gene; GRE, GR responsive element; MMP, matrix metalloproteinase;
PGX-3, plasma glutathione peroxidase-3; TPA, 12-O-tetradecanoyl-phor-
bol-13-acetate.
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GR to interfere with other transcription factors plays an
essential role for normal functions in the body.
Down-modulation of the activity of transcription fac-
tors, such as AP-1 and NF
 
k
 
B, is thought to mediate the an-
tiinflammatory and antitumor promoting activities of GCs.
Although different lines of evidence have suggested an im-
portant role of both, the transactivation and the antiapop-
totic activities of NF
 
k
 
B in cell transformation (Foo and
Nolan, 1999), a direct role of NF
 
k
 
B in the induction of ex-
perimentally induced carcinogenesis in skin, has not yet
been demonstrated. In contrast, the lack of malignant pro-
gression during skin tumor development in 
 
c-fos
 
2
 
/
 
2
 
 mice
(Saez et al., 1995) strongly underlines the requirement of
AP-1–regulated gene expression in this process. High con-
stitutive expression levels of AP-1 target genes, such as in-
terstitial collagenase (MMP-13) and stromelysin-1 (MMP-
3), were observed in skin tumors (Basset et al., 1997). In
tissue culture cells, repression of interstitial collagenase
and stromelysin expression by dexamethasone is mediated
through negative interference between AP-1 and GR
(Beato et al., 1995; Dumont et al., 1998; Karin, 1998).
Whether the DNA binding-dependent or -independent
function of the GR is required for repression of tumor
promotion and phorbol ester-induced gene expression in
the animal is still unclear.
Here, we have measured phorbol ester- and GC-induced
changes in MMP-13 and MMP-3 gene expression in mouse
skin to analyze mutual interference between AP-1 and GR
in vivo. Both genes contain functional AP-1 sites, which
are essential for upregulation by many growth stimulating
agents in tissue culture (Angel and Karin, 1991). MMP-13
appears to represent the most selective reporter gene to
measure AP-1 activity: in 
 
c-fos
 
 transgenic mice, expression
of MMP-13 is enhanced, whereas in 
 
c-fos
 
 knockout mice,
the level of MMP-13 transcripts is reduced (Gack et al.,
1994; Porte et al., 1999). Second, phorbol ester-dependent
induction of MMP-13 is almost completely lost in fibro-
blasts from 
 
c-fos
 
 and 
 
c-jun
 
 knockout embryos (Hu et al.,
1994; Schreiber et al., 1995). Finally, the AP-1 site in the
murine MMP-13 promoter is necessary and sufficient for
12-O-tetradecanoyl-phorbol-13-acetate (TPA)-dependent
induction (Porte et al., 1999), demonstrating that other
transcription factors, including NF
 
k
 
B, whose activities
have been found to be affected by phorbol esters (Nelsen
et al., 1988), do not contribute to phorbol ester-dependent
induction of this gene.
By the analysis of MMP-13 and MMP-3 gene expression
in skin of phorbol ester- and GC-treated wild-type and
GR
 
dim
 
 mice, we could demonstrate that AP-1 activity is re-
pressed by the GR in vivo. Since induction of both genes is
considered a hallmark of altered gene expression during
mouse skin carcinogenesis, these data strongly suggest that
the ability of GR to undergo protein–protein interaction
with transcription factors, such as AP-1, is responsible for
the antitumor promoting activity of GCs.
 
Materials and Methods
 
Animals
 
The dorsal skin of 7–9-wk-old female C57BL/6J mice (BRL) or GR
 
dim
 
mice (Reichardt et al., 1998) was shaved 4 d before experimentation. Mice
were treated topically with 1–10 nmol TPA or with 50 
 
m
 
g dexamethasone
(Sigma Chemical Co.) dissolved in 200 
 
m
 
l acetone. The animals were
killed 0–6 h after application.
 
Northern Blot Analysis
 
Skin tissues were homogenized and RNA was prepared as described pre-
viously (Reichardt et al., 1998) and analyzed by Northern blot (Gack et al.,
1994; Schreiber et al., 1995). The probes for 18 S rRNA, HSP-27, and
plasma glutathione peroxidase-3 (PGX-3) were obtained by reverse tran-
scriptase PCR using a mouse skin RNA preparation.
 
In Situ Hybridization and Immunohistochemistry
 
6-
 
m
 
m paraffin sections from skin biopsies were subjected to in situ hybrid-
ization using 
 
35
 
S-UTP–labeled sense and antisense probes of MMP-13 and
MMP-3 as described in Gack et al. (1995). Immunohistochemistry was
performed using a polyclonal rabbit anti–mouse GR antibody (M20; Santa
Cruz), followed by an ABC staining procedure (ABC Rabbit IgG Kit;
Vector Labs, Inc.) according to the manufacturer’s instructions.
 
cDNA Expression Array Hybridization
 
Atlas™ mouse cDNA expression array I filters were hybridized with ra-
dioactively labeled first strand cDNA following the specifications of the
manufacturer (CLONTECH). Differences in expression patterns were an-
alyzed using AIS software and Array Vision software module (Imaging
Research).
 
Results
 
Rapid Induction of MMP-13 and MMP-3 Gene 
Expression by TPA in Mouse Skin
 
To establish an in vivo experimental system suitable to
measure AP-1–dependent gene expression and to study
mutual interference between AP-1 and GR in the animal,
we first determined expression of MMP-3 and MMP-13 in
mouse skin after treatment with TPA. In mock-treated an-
imals, transcription levels of MMP-3 and MMP-13 were
barely detectable (Fig. 1 a). Upon application of TPA, an
up to 100-fold induction of both genes was observed
Figure 1. TPA induces MMP-13 and MMP-3 in skin. a, TPA (10
nmol) in acetone was applied to the back skin. After 0, 1, 4, and
6 h, mice were killed and RNA from skin was prepared. MMP-13,
MMP-3,  c-jun, and c-fos expression was analyzed by Northern
blot analysis. b, TPA (0.1, 1, 10, and 50 nmol) was applied as de-
scribed in a, and animals were killed after 6 h and analyzed by
Northern blot analysis. Rehybridization with a cDNA fragment
of 18 S RNA was performed serving as a loading control. 
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within four to six hours. Induction of both genes is dose-
dependent, reaching maximal levels at 10 nmol, whereas 1
nmol of TPA was not sufficient for potent induction (Fig. 1
b). Furthermore, upregulation was preceded by transcrip-
tional activation of the main regulators of MMP-3 and
MMP-13 gene expression, 
 
c-jun
 
 and 
 
c-fos
 
. Induction of
these immediate early genes was already detectable within
one hour and declined at four hours in the case of 
 
c-jun
 
,
and between four and six hours for 
 
c-fos
 
 (Fig. 1 a).
To identify the specific cell type responsible for en-
hanced MMP-13 and MMP-3 gene expression in response
to TPA, in situ hybridization analysis of parallel transver-
sal sections of skin biopsies was performed. Whereas in
untreated skin, no significant signals for the expression of
MMP-13 and MMP-3 could be detected (data not shown),
both genes were highly induced in a cell type-specific man-
ner upon phorbol ester treatment (Fig. 2). MMP-13 tran-
scripts were observed in the epidermis only in a subset of
basal keratinocytes (Fig. 2, a and b). MMP-3 expression
was found exclusively in monocytic cells in the dermal
Figure 2. Cell type-specific
expression of MMP-13,
MMP-3, and GR in skin of
TPA-treated mice. In situ hy-
bridization for MMP-13 (a
and b) and MMP-3 (c and d)
on transverse sections of the
skin from female C57BL/6
mice treated for 6 h with
TPA. Dark-field (a) and
bright-field (b) illumination
of a section hybridized with a
MMP-13 specific riboprobe.
The arrow indicates nuclei
from fibroblasts. Dark-field
illumination (c) and bright-
field (d) illumination of a skin
section hybridized with a
MMP-3 specific riboprobe.
e–h, Immunohistochemical
analysis of GR expression us-
ing anti-mouse GR antibody
(e and g) or secondary anti-
rabbit IgG antibody alone (g
and h). The arrow indicates
nuclei from fibroblasts. ep,
Epidermis; de, dermis. Bars:
(a, c, e, and g) 100 mm; (b, d,
f, and h) 20 mm. 
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compartment (Fig. 2, c and d). Interestingly, in contrast to
primary and immortalized skin fibroblasts showing en-
hanced expression of both genes in response to TPA
(Clark et al., 1985; Wilhelm et al., 1987), neither MMP-13
nor MMP-3 transcripts were found in fibroblasts of the
dermis (Fig. 2, b and d).
 
Repression of TPA-induced Genes by Glucocorticoids
in Skin
 
We next wanted to investigate whether GR could interfere
with AP-1 activity under these conditions. Since the ex-
pression pattern of GR in murine skin has not yet been de-
scribed, we first wanted to confirm the presence of GR in
MMP-3– and MMP-13–expressing cells in the skin by im-
munohistochemistry. Strong expression of GR protein was
observed throughout the epidermis (Fig. 2, e and f) and in
mononuclear cells in the dermis (Fig. 2 f). Weaker signals
for GR protein were observed in dermal fibroblasts (Fig. 2
f). These data show that GR is expressed by a broad range
of cells in the skin, including MMP-13 and MMP-3 positive
cells. Therefore, TPA-induced expression of MMP-13 and
MMP-3 in skin in the presence or absence of GC is an ap-
propriate system to measure GR-specific inhibition of
gene expression in vivo. Consequently, we asked whether
TPA-induced expression of MMP-13 and MMP-3 is re-
pressed by dexamethasone in these cells. We found a com-
plete inhibition of induction of both genes in skin after
concomitant treatment with TPA and dexamethasone in
skin (Fig. 3 a).
 
Repression of Gene Transcription by the GR Does Not 
Require DNA Binding of the Receptor
 
To analyze in more detail the molecular mechanism re-
sponsible for the repression of AP-1–dependent genes by
GC in skin, we took advantage of GR
 
dim
 
 mice. These mice
carry a DNA binding-defective GR. Previously, transient
transfection studies in tissue culture cells suggested that
the DNA binding function of the GR is not required for
transrepression of AP-1–mediated transcription (Heck et al.,
1994). However, in light of the lack of induction of MMP-3
and MMP-13 expression by TPA in dermal fibroblasts in
vivo (Fig. 2) and the complex regulatory processes present
 
in skin, it is still possible that both DNA binding-depen-
dent and -independent functions of GR are required for
repression of TPA-induced expression of MMP-3 and
MMP-13 in skin cells. To determine the importance of ei-
ther one of these functions of GR, we analyzed the expres-
sion of both genes in GR
 
dim
 
 mice. Expression of both
MMP-3 and MMP-13 is dramatically induced upon TPA
treatment in GR
 
dim
 
 mice, similar to wild-type mice. In situ
hybridization analysis confirmed that induction of these
genes in GR
 
dim
 
 mice originates from basal keratinocytes
and monocytic cells (data not shown), resembling the pat-
tern of expression in wild-type mice (Fig. 2). Interestingly,
induction was completely repressed by dexamethasone in
both wild-type and GR
 
dim
 
 mice (Fig. 3 a), which strongly
suggests that the DNA binding-dependent function of the
GR is not required for repression of TPA-induced MMP
gene expression in vivo.
GR has been reported to either activate (Jonat et al.,
1990) or repress 
 
c-jun
 
 expression (Wei et al., 1998) in tis-
sue culture cells, depending on the cell type. To confirm
that GR-dependent repression of MMP-3 and MMP-13
cannot be explained by a loss of 
 
c-jun
 
 and/or 
 
c-fos 
 
ex-
pression upon hormone treatment, we measured the level
of 
 
c-fo
 
s and 
 
c-jun
 
 transcripts in unstimulated and stimu-
lated mouse skin. Significant basal level of 
 
c-jun
 
 tran-
scripts can be detected in wild-type and GR
 
dim
 
 mice, which
became further enhanced upon TPA treatment (Fig. 3 b).
Induction of 
 
c-fos
 
 was even more pronounced. Expression
of c-
 
jun
 
, but not 
 
c-fos
 
, was significantly induced by dexa-
methasone in both wild-type and GR
 
dim
 
 mice, which might
be mediated by the DNA binding-independent, positive
function of GR on Jun/Jun homodimers (Miner and
Yamamoto, 1992; Teurich and Angel, 1995) binding to the
 
c-jun
 
 promoter. Most importantly, dexamethasone re-
duced TPA-induced expression of 
 
c-fos
 
 and 
 
c-jun
 
 only
slightly (Fig. 3 b). The presence of 
 
c-jun
 
 and 
 
c-fos
 
 tran-
scripts in TPA- and dexamethasone-treated animals con-
firmed that repression of phorbol ester-induced MMP-3
and MMP-13 expression is most likely due to inhibition of
AP-1 activity by GR and cannot be explained by a loss
of expression of the critical AP-1 components c-Jun and
c-Fos.
 
Positive Regulation of PGX-3 and HSP27 by GC in 
Mouse Skin Is Absent in GR
 
dim
 
 Mice
 
To prove abrogation of GR-mediated transactivation
function in GR
 
dim
 
 mice, we aimed to detect differences in
GC-dependent regulation of GR target genes in skin cells
of wild-type and GR
 
dim
 
 mice. Therefore, we performed
gene expression profiling on a mouse Atlas™ cDNA ex-
pression array. Filters containing spotted DNA from 588
known genes were hybridized in parallel with radiolabeled
cDNA derived from RNA of skin from untreated and
dexamethasone-treated mice. Among the differentially
expressed genes (data not shown), two examples, PGX-3
and HSP-27, were analyzed by Northern blot analysis (Fig.
4). In the skin of wild-type mice, expression of both PGX-3
and HSP-27 was significantly upregulated (4.3- and 2.9-
fold, respectively) six hours after dexamethasone treat-
ment. Enhanced levels of PGX-3, but not HSP-27, already
were detectable after 1.5 hours (data not shown). Impor-
Figure 3. The DNA binding function of the GR is dispensable
for repression of MMP-13 and MMP-3 induction in vivo. Wild-
type (wt) or GRdim mice were treated with acetone (Co), 50 mg
dexamethasone (Dex), 10 nmol TPA (TPA), or 10 nmol TPA
with 50 mg dexamethasone (T1D). Animals were killed after 6 h
(a) or 1.5 h (b) and analyzed by Northern blot. 
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tantly, in GR
 
dim
 
 mice, almost no elevation in mRNA levels
of PGX-3 and HSP-27 is detectable (Fig. 4).
Taken together, negative interference of AP-1 by GR
does not require the DNA binding function in vivo, since in
wild-type and in GR
 
dim
 
 mice, MMP-13 and MMP-3 are
equally repressed, whereas genes positively regulated are ac-
tivated by GC only in wild-type mice, but not in GR
 
dim
 
 mice.
 
Discussion
 
We established an experimental system to induce tran-
scription of the AP-1–dependent genes MMP-13 (collage-
nase-3) and MMP-3 (stromelysin-1) in skin by the applica-
tion of TPA. In line with the critical role of de novo
synthesis of c-Jun and c-Fos for full transcriptional activa-
tion of interstitial collagenases (Angel and Karin, 1991),
we found a rapid upregulation of 
 
c-jun
 
 and 
 
c-fos
 
 mRNA
upon TPA treatment in skin (Kennard et al., 1995).
In contrast to the coordinate induction of both genes in
tissue culture cells (Angel and Karin, 1991), the expression
pattern of MMP-13 and MMP-3 genes in the skin was re-
stricted to distinct cell types. MMP-13 was expressed upon
TPA treatment in basal keratinocytes, which are the sites
of expression of MMP-13 observed during wound healing
in mice (Madlener et al., 1998). TPA-induced MMP-3 ex-
pression was mainly found in monocytic cells in the dermal
compartment. However, we could not detect expression of
MMP-3 in the basal layer of the epidermis by in situ
hybridization, although others have observed MMP-3
expression in fractionated keratinocytes derived from
TPA-treated epidermis (Krieg et al., 1988). During experi-
mental wound healing, induction of MMP-3 has been
found in some cells of the mesenchymal compartment of
the skin and in basal keratinocytes after 24 hours (Madle-
ner et al., 1998). Thus, most likely MMP-3 induced by TPA
treatment only partially reflects the expression pattern ob-
served during wounding. Surprisingly, in contrast to fibro-
blasts in tissue culture (Wilhelm et al., 1987; Madlener et
al., 1998), we found no induction of either MMP-13 or
MMP-3 in dermal fibroblasts upon TPA treatment of skin.
The specific microenvironment composed of soluble fac-
tors and components of the extracellular matrix obviously
does not allow the responsiveness of these cells to TPA by
induced expression of MMPs. The molecular mechanism
controlling cell type-specific upregulation of MMP-13 and
MMP-3 transcripts in the skin remains to be elucidated.
 
Importantly, the phorbol ester-induced expression of
MMP-13 and MMP-3 was efficiently inhibited by GCs in a
cell type-specific manner. To analyze if DNA binding of
the GR is involved in this downregulation of MMP-13 and
MMP-3 in vivo, we made use of GR
 
dim
 
 mice. To address
the question whether gene activation by GCs is indeed im-
paired in GR
 
dim
 
 mice, we identified GC-induced genes in
the skin using a high-density filter screening approach.
PGX-3 and HSP27 were among the strongest induced
genes and as yet have not been described to be responsive
to GCs. For both PGX-3 and HSP27, we could show a fail-
ure of GC-mediated upregulation in GR
 
dim
 
 mice.
In contrast to loss of GC-dependent gene activation
GR
 
dim
 
 mice, TPA-mediated expression of AP-1 target
genes, such as MMP-13, MMP-3, and MMP-9 (gelatinase
B; data not shown) is efficiently downregulated by dexa-
methasone. Obviously, the DNA binding function of GR
and subsequent transcriptional activation of GRE-depen-
dent genes is not required for transrepression of AP-1 in
vivo. The presence of 
 
c-fos
 
 and 
 
c-jun
 
 transcripts upon
cotreatment with TPA and dexamethasone suggests that
the de novo synthesis of both AP-1 components is not
abolished by GCs. Specifically, induction of 
 
c-jun
 
 by TPA,
which requires the activity of MAP kinases, such as JNK,
to hyperphosphorylate preexisting c-Jun protein, was not
repressed by GCs. Thus, inhibition of the JNK pathway by
GR, which was described in tissue culture cells (Caelles
et al., 1997), may not play a major role in vivo, at least in
skin.
In transgenic mice, overexpression of 
 
c-jun 
 
and
 
 c-fos
 
, as
well as tissue-specific expression of the AP-1 target genes,
human collagenase and stromelysin, induces, or at least
enhances, tumorigenesis (Wang et al., 1991, 1995; D’Ar-
miento et al., 1995; Sternlicht et al., 1999). Downregula-
tion of AP-1 target gene expression has been proposed to
be a crucial event in GC-mediated inhibition of tumor for-
mation in the multiple stage model of carcinogenesis in
skin (Jonat et al., 1990). Here, we demonstrate that TPA,
one of the most potent and best characterized tumor pro-
moters in mouse skin carcinogenesis, induces MMP-13 and
MMP-3 very rapidly at the same dosage, which is, when
applied periodically, optimal to mediate tumor formation
(Fürstenberger and Kopp-Schneider, 1995). The critical
role of AP-1 in MMP-13 and MMP-3 expression and the
downmodulation of expression of both genes by GCs
strongly suggest that transrepression of AP-1 activity is a
key feature of antitumor promoting activity of GCs. The
finding that this activity of GR does not require the DNA
binding function might be highly valuable in the search for
better therapeutical strategies of GC application in skin
carcinogenesis and related diseases.
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Figure 4. Induction of HSP-27
and plasma glutathione peroxi-
dase 3 requires the DNA bind-
ing function of the GR. Control
(Co) and dexamethasone (50
mg; Dex) treated wild-type (wt)
or GRdim mice were killed after
6 h and RNA from back skin
was analyzed for PGX-3 and
HSP-27 expression by Northern
blot. 
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